参考文献/References:
[1] 张丽,罗荔,陆春晖,等.血清缺氧诱导因子-1α,髓鞘碱性蛋白和超敏c反应蛋白在糖尿病周围神经病变中的变化及临床意义[J].中国医药导报,2017,14(15):174-178.
[2] 马敬弟.2型糖尿病患者血清缺血修饰白蛋白与颈动脉内膜中层厚度的关系[J].实用老年医学,2014,28(9):742-744.
[3] 张春风,葛焕琦,谢云,等.高敏C反应蛋白对2型糖尿病周围神经病变发病风险的影响[J].中国糖尿病杂志,2016,24(9):787-791.
[4] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[J].中国医学前沿杂志:电子版,2011,10(6):54-109.
[5] 戴自英.实用内科学[M].第9版.北京:人民卫生出版社,1994:622-628.
[6] Vidhya G, Anusha B. Diaretionpathy database-A gene database for diabetic retinopathy[J]. Bioinformation, 2014,10(4):235-240.
[7] 魏剑芬,吴乃君,陈冬,等.糖尿病周围神经病变患者血清铁蛋白与氧化应激反应的相关性[J].广东医学,2014,35(18):2887-2889.
[8] Trippe BS, Barrentine LW, Curole MV, et al. Nutritional management of patients with diabetic peripheral neuropa-thy with metanx: results of a real-world patient experi-ence trial[J]. Curt Med Res Opin, 2016, 32(2):1-28.
[9] 魏剑芬,王颖,吴乃君,等.糖尿病周围神经病变患者血清神经元特异性烯醇化酶与神经传导速度的关系[J].中国糖尿病杂志,2016,24(6):528-531.
[10] Hewston P, Deshpande N. Falls and balance impairments in older adults with type 2 diabetes: thinking beyond diabetic peripheral neuropathy[J]. Canadian Journal of Diabetes, 2016, 40(1):6-9.
[11] Vinik AI, Shapiro DY, Rauschkolb CA, et al. A randomized withdrawal, Placebo-Controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy[J]. Diabetes Care, 2014, 37(8):2302-2309.
[12] 罗一青,李娜,圈启芳,等.老年2型糖尿病伴周围神经病变患者IL-1β,HCY,Cys-C,HbA1c水平研究[J].国际检验医学杂志,2018,39(12):1425-1428.
[13] 曹辉彩,王雅宁,张志强,等.缺血修饰白蛋白,糖化白蛋白和糖化血红蛋白与2型糖尿病合并视网膜病变的相关性研究[J].中国医药导报,2017,14(15):72-75.
[14] 孙华,徐治国,翟羽佳.2型糖尿病和急性心肌缺血患者缺血修饰性白蛋白水平比较分析[J].中国地方病防治杂志,2018,33(3):297-298.
[15] Adams AS, Parker MM, Moffet HH, et al. Communication barriers and the clinical recognition of diabetic peripheral neuropathy in a diverse cohort of adults: the distance study[J]. Journal of Health Communication, 2016, 21(5):544-553.